Scilex Holding (SCLX) Accounts Payables (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Accounts Payables of $2.5 million for Q1 2026, up 1574.15% year-over-year from $147000.0 in Q1 2025, and up 17.86% quarter-over-quarter from $2.1 million in Q4 2025.
Scilex Holding (SCLX) Accounts Payables (2021 - 2026) Analysis & Trends
Scilex Holding's Accounts Payables history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 1574.15% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (up 1574.15% YoY), while the FY2025 annual figure was $2.1 million, down 96.03% from the prior year.
- Accounts Payables for Q1 2026 stood at $2.5 million, up from $2.1 million in the prior quarter.
- The five-year high for Accounts Payables was $67.4 million in Q3 2025, with the low at $41003.0 in Q1 2022.
- The 5-year median for Accounts Payables is $960000.0 (2023), against an average of $17.8 million.
- Peak annual rise in Accounts Payables reached 53473.08% in 2024, while the deepest fall reached 98.94% in 2024.
- Scilex Holding's Accounts Payables stood at $79000.0 in 2022, then surged by 51740.51% to $41.0 million in 2023, then increased by 28.49% to $52.6 million in 2024, then tumbled by 96.03% to $2.1 million in 2025, then rose by 17.86% to $2.5 million in 2026.
- Business Quant data shows SCLX's Accounts Payables at $2.5 million in Q1 2026, $2.1 million in Q4 2025, and $67.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 121.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.46 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Sep 30, 2025 | 67.36 Mn |
| Jun 30, 2025 | 59.16 Mn |
| Mar 31, 2025 | 147,000.00 |
| Dec 31, 2024 | 52.62 Mn |
| Sep 30, 2024 | 346,000.00 |
| Jun 30, 2024 | 41.79 Mn |
| Mar 31, 2024 | 354,000.00 |
| Dec 31, 2023 | 40.95 Mn |
| Sep 30, 2023 | 32.56 Mn |
| Jun 30, 2023 | 78,000.00 |
| Mar 31, 2023 | 960,000.00 |
| Dec 31, 2022 | 79,000.00 |
| Sep 30, 2022 | 809,292.00 |
| Jun 30, 2022 | 598,646.00 |
| Mar 31, 2022 | 41,003.00 |
| Dec 31, 2021 | 4.28 Mn |
| Sep 30, 2021 | 43,569.00 |
| Jun 30, 2021 | 20,025.00 |